ScholarIQanswers from OpenAlex & ORCID
Sarah E. Pinder
ResearcherPublications, citations & collaboration network
Sarah E. Pinder is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sarah E. Pinder have?
ScholarIQindexed works
Sarah E. Pinder has 779 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sarah E. Pinder have?
ScholarIQcitation count
Sarah E. Pinder has 42,578 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sarah E. Pinder?
ScholarIQh-index
Sarah E. Pinder has an h-index of 95 in OpenAlex.
What is the i10-index of Sarah E. Pinder?
ScholarIQi10-index
Sarah E. Pinder has an i10-index of 311 in OpenAlex.
What is the ORCID of Sarah E. Pinder?
ScholarIQorcid
The ORCID for Sarah E. Pinder is on the source record.
What is the OpenAlex record for Sarah E. Pinder?
ScholarIQopenalex
The OpenAlex for Sarah E. Pinder is on the source record.
What are the most-cited papers on Sarah E. Pinder?
ScholarIQmost cited works
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin, Gulisa Turashvili, Oscar M. Rueda, Mark Dunning, Doug Speed, Andy G. Lynch, Shamith Samarajiwa, Yinyin Yuan, Stefan Gräf, Gavin Ha, Gholamreza Haffari, Ali Bashashati, Roslin Russell, Steven McKinney, Anita Langerød, Andrew R. Green, Elena Provenzano, Gordon Wishart, Sarah E. Pinder, Peter H. Watson, Florian Markowetz, Leigh C. Murphy, Ian O. Ellis, Arnie Purushotham, Anne‐Lise Børresen‐Dale, James D. Brenton, Simon Tavaré, Carlos Caldas, Samuel Aparício
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
Bernard Pereira, Suet‐Feung Chin, Oscar M. Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen‐John Sammut, Dana W.Y. Tsui, Bin Liu, Sarah‐Jane Dawson, Jean Abraham, Helen Northen, John F. Peden, Abhik Mukherjee, Gulisa Turashvili, Andrew R. Green, Steve McKinney, Arusha Oloumi, Sohrab P. Shah, Nitzan Rosenfeld, Leigh C. Murphy, David Bentley, Ian O. Ellis, Arnie Purushotham, Sarah E. Pinder, Anne‐Lise Børresen‐Dale, Helena Earl, Paul D.P. Pharoah, Mark T. Ross, Samuel Aparício, Carlos Caldas
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt, Holly Tovey, Maggie C.U. Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazińska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett‐Lee, Robert Brown, Stephen Chan, Mitch Dowsett, James M. Flanagan, Lisa Fox, Anita Grigoriadis, Alexander Gutin, Catherine Harper‐Wynne, M. Hatton, Katherine A. Hoadley, Jyoti Parikh, Peter J. Parker, Charles M. Perou, Rebecca Roylance, Vandna Shah, Adam Shaw, Ian E. Smith, Kirsten M. Timms, Andrew Wardley, G. Wilson, Cheryl Gillett, Jerry S. Lanchbury, Alan Ashworth, Nazneen Rahman, Mark Harries, Paul Ellis, Sarah E. Pinder, Judith M. Bliss
Addressing overtreatment of screen detected DCIS; the LORIS trial
Adele Francis, Jeremy Thomas, Lesley Fallowfield, Matthew Wallis, John M.S. Bartlett, Cassandra Brookes, Tracy Roberts, Sarah Pirrie, Claire Gaunt, Jennie Young, Lucinda Billingham, David Dodwell, Andrew M. Hanby, Sarah E. Pinder, Andrew Evans, Malcolm Reed, Valerie Jenkins, Lucy Matthews, Maggie Wilcox, Patricia Fairbrother, S. Bowden, Daniel Rea